Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis

Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis

Background: Antipsychotics modulate expression of inflammatory cytokines and inducible inflammatory enzymes. Elopiprazole (a phenylpiperazine antipsychotic drug in phase 1) has been characterized as a therapeutic drug to treat SARS-CoV-2 infection in a repurposing study. We aim to investigate the po...

Full description

Bibliographic Details
Main Authors: Benedicto Crespo-Facorro, Miguel Ruiz-Veguilla, Javier Vázquez-Bourgon, Ana C. Sánchez-Hidalgo, Nathalia Garrido-Torres, Jose M. Cisneros, Carlos Prieto, Jesus Sainz
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Pharmacology
Subjects:
psychosis
inflammation
immunology
coronavirus
repurposing drugs
elopiprazole
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.646701/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.646701/full

Similar Items